Ads
related to: spironolactone vs eplerenone for hypertension diabetes- View Patient Stories
Watch Videos of Patient Stories
Today to Start Your T1D Journey.
- See the FAQs
Get the Answers to Frequently
Asked Questions Today.
- Join the Support Program
View Resources & Copay Assistance.
Terms & Conditions Apply.
- Talk to Your Doctor
Download the Discussion Guide
to Start the Conversation Today.
- View T1D Organizations
Stay Connected. Learn About
T1D Organizations Today.
- Get Screened Today
Discover the Importance of Early
Screening. Learn More Now.
- View Patient Stories
Search results
Results From The WOW.Com Content Network
Spironolactone has been identified as an inhibitor of NRG1‐ERBB4 signaling. [142] Spironolactone has been found to act as a potent inhibitor of the pannexin 1 channel, and this action appears to be involved in its antihypertensive effects independently of MR antagonism. [143] Spironolactone has been found to block hERG channels. [144]
Unlike the related medication eplerenone, spironolactone is said to not be metabolized by CYP3A4. [245] However, hepatic CYP3A4 is likely responsible for the 6β-hydroxylation of 7α-TMS into 6β-OH-7α-TMS. [18] [246] 7α-TMS may also be hydroxylated at the C3α and C3β positions. [19] Spironolactone is dethioacetylated into canrenone. [20]
Eplerenone may have a lower incidence than spironolactone of sexual side effects such as feminization, gynecomastia, impotence, low sex drive and reduction of size of male genitalia. [18] This is because other antimineralocorticoids have structural elements of the progesterone molecule, causing progestogenic and antiandrogenic outcomes. [ 4 ]
Potassium-sparing diuretics act to prevent sodium reabsorption in the collecting tubule by either binding ENaCs (amiloride, triamterene) or by inhibiting aldosterone receptors (spironolactone, eplerenone). This prevents excessive excretion of K + in urine and decreased retention of water, preventing hypokalemia. [10]
Diabetes Diabetes with CVD risk <140/90 <130/80 ACEI/ARB, thiazide-like diuretic, and/or dihydropyridine CCB ESC / ESH 2018 [12] General age <65 General age ≥65 <130/80 <140/80 Thiazide-type diuretic, ACEI/ARB, and/or CCB CAD: add beta-blocker Resistant hypertension: add spironolactone ACC / AHA 2017 [13] General <130/80
Eplerenone is a newer drug that was developed as a spironolactone analog with reduced adverse effects. In addition to the y-lactone ring and the substituent on C-7, eplerenone has a 9α,11α-epoxy group. This group is believed to be the reason why eplerenone has a 20-40-fold lower affinity for the mineralocorticoid receptor than spironolactone. [7]